Vemurafenib (PLX4032), a potent inhibitor of BRAF V600E that is recommended for cases of late-stage melanoma, prolonged patients’ overall survival from 9.9 to 13.2 months compared to standard chemotherapy [7]. This evidence concerns the gene BRAF and melanoma.